Dynacure, a French Phase 1/2 biotech developing therapies for neuromuscular diseases, filed on Friday with the SEC to raise up to $100 million.
Dynacure is initially focused on developing treatments for neuromuscular diseases, beginning with myotubular and centronuclear myopathies (CNM). Its lead candidate, DYN101, is an antisense oligonucleotide designed to be a disease-modifying medicine for treatment of the majority of CNM patients across multiple mutations in both adult and pediatric populations. The company is conducting a Phase 1/2 trial in Europe of DYN101, and intends to expand this trial to sites in the US in the 2H21. It expects to report interim pharmacokinetic and safety data in the 2H22 and final data in 2023.
The Illkirch-Graffenstaden, France-based company was founded in 2016 and plans to list on the Nasdaq under the symbol DYCU. J.P. Morgan, BofA Securities, and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.